-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Regeneron Pharmaceuticals confirmed today that, as the White House press secretary announced, under the principle of "compassionate use," Regeneron provided 8 grams of REGN-COV2 for President Trump to use.
REGN-COV2 is a mixture of two monoclonal antibodies (REGN10933 and REGN10987), specifically designed to block the infection process of SARS-CoV-2 (the virus that causes COVID-19) and is a COVID-19 research therapy.
company's current priority is to maintain sufficient supply of REN-COV2 for rigorous clinical trials to fully assess its safety and effectiveness.
, however, there are limited products approved for "compassional use" in exceptional circumstances.
"compassion for use" must be made by the attending physician.
is currently evaluating the effectiveness and safety of REN-COV2 for the treatment and prevention of COVID-19.
clinical trials are actively recruiting hospitalized and non-hospitalized patients, as well as people at high risk of COVID-19 infection.
week, Regeneron announced early data showing that the use of REGENN-COV2 treatment in unpatientED-19 patients reduced viral levels and improved symptoms.
.